• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    A pharmaceutical lozenge for the modified release of active compounds in the gastrointestinal tract is described, with active-compound-containing particles which have a first coating controlling the release and a further, outer coating with saliva-resistant properties. The first coating, which controls the release of active compound, can have release-delaying or enteric properties.
    公开号:US20010001668A1
    申请号:US09/308,429
    申请日:1997-11-17
    公开日:2001-05-24
    发明作者:Karsten Cremer
    申请人:LTS Lohmann Therapie Systeme GmbH and Co KG；
    IPC主号:A61K9-0056
    专利说明:
    [0001] The invention relates to a pharmaceutical lozenge for the modified release of active compounds in the gastrointestinal tract, with active-compound-containing particles which have a first coating controlling the release and a further, outer coating with saliva-resistant properties. [0001]
    [0002] Orally administrable presentation forms having modified active compound release can serve various therapeutic aims. The most frequent aims are the protection of the gastric mucosa from a harmful active compound or the protection of the active compound from the acidic medium in the stomach on the one hand, which is brought about by enteric coatings; moreover the control of the release rate over a relatively long time, which can be achieved by various release-delaying measures and leads to plasma levels with relatively low variations, a better tolerability as a result and a longer efficacy of the administration. [0002]
    [0003] A formulation with modified active-compound release cannot be equally easily developed in the case of all pharmacologically suitable active substances. As a rule, it necessitates a number of additives with the aid of which the desired effects can be achieved. These additives correspondingly clearly increase the mass of the presentation form. In presentation forms with prolonged release of active compound, the dose to be administered is additionally increased compared to a simple presentation form. In the case of various active compounds, on account of their dose, no presentation forms having prolonged release of active compound could be developed using the possibilities known until now, since they could not be swallowed in the form of a capsule or tablet because of the resulting dimensions. Thus various antibiotics, for example, must still be orally administered three to four times daily although it is known that in the case of administration more than twice daily the reliability of taking by patients is low. In the case of antibiotics, the non-delayed-release single dose is frequently already 500 to 1000 mg, which together with the auxiliaries necessary for pharmaceutical formulation leads to capsules or tablets which can only be swallowed with difficulty. A delayed-release preparation prepared on the basis of conventional techniques with more than 1000 mg of active compound and an increased content of auxiliaries can virtually no longer be swallowed. [0003]
    [0004] The provision of a presentation form which is easy and pleasant to take with modified release of active compound, which is also suitable for active compounds which have to be taken in high single doses, is desirable. [0004]
    [0005] According to the invention, the problem of the taking of high doses should first of all be solved by administering a multiparticulate active compound preparation which is compressed to give a lozenge, whose particles are individually coated to achieve a modified release. The coated particles are released in finely divided form on sucking the tablet in the mouth and can be easily swallowed with the saliva. [0005]
    [0006] The presentation form of the lozenge has been known for a long time and is frequently used in order to deliver active compounds to the diseased oral and pharyngeal mucosa. The lozenge can also be suitable for systemically active substances if the substances have a pleasant taste and are to be absorbed without delay. For the solution of the problem, the presentation form of the lozenge is employed, since it is able to accommodate more active-compound and auxiliary mass without loss of its administrability than a tablet intended for swallowing. Lozenges having a mass of more than 4 g are on the market and are apparently accepted by patients without problem. [0006]
    [0007] In principle, the prior art allows the compression of coated particles having modified release of active compound, although the intended use according to the invention with its advantages—administration as a lozenge with suitability even for high doses of active compound—was neither recognized nor described as a solution of the problem presented above. [0007]
    [0008] Thus the Patent Applications EP 153 104 and EP 355 247 teach, for example, the compression of release-delaying coated particles containing active compound to give tablets, a process which is also described in other sources. Moreover, the U.S. Pat. No. 5,464,632 discloses a rapidly disintegrating tablet intended for sucking or for disintegration in the mouth, which contains the active compound optionally in the form of coated particles for modified release. However, with this tablet in the case of disintegration in the mouth it is to be expected that portions of the active compound have already been released through the coating of the particles into the oral cavity and in the course of this leave behind an adverse taste impression. [0008]
    [0009] Analogously, the presentation form of the lozenge, as is claimed in the present invention, does also solve, on the one hand, the problem of the administrability of relatively large amounts of active compound and auxiliaries, but on the other hand creates new problems. For one thing, in the case of enteric-coated particles the coatings are exposed to the pH-neutral saliva, as a result of which they prematurely disintegrate and can no longer achieve the desired protective effect in the stomach. For another thing, in the case of particles which are provided with release-delaying coatings, portions of the active compound have already been released in the oral cavity by diffusion, which is not acceptable, in particular in the case of unpleasantly tasting substances. [0009]
    [0010] A need therefore exists for a further improved presentation form having modified release of active compound for administration of high doses of active compound, which does not have the disadvantages mentioned. This object, on which the invention is based, is achieved by a pharmaceutical presentation form according to one of the two main claims: in addition to the special design as a lozenge, the tablet according to the invention overcomes the disadvantages of the prior art in that its active compound is present in the form of doubly or two-layer coated particles, a first, inner coating serving for the release of the modified active compound, while a further, external coating is saliva-resistant, but dissolves in the acidic medium of the stomach and thereby ensures that during the sucking of the tablet active compound is not released into the oral cavity. The first, inner coating of the particles can modify the release of active compound according to one of the two main claims either in that the release commences only after the gastric passage of the particle, or it can be designed as a membrane which is insoluble in the gastric and intestinal juice, but through which the active compound can slowly diffuse outwards and be released with a delay. [0010]
    [0011] According to the invention, the active-compound-containing particles are pressed together with suitable auxiliaries to give lozenges which, owing to their composition, slowly erode in the mouth and in the course of this release the particles into the saliva. The saliva containing the coated particles is then swallowed. Self-experiments showed that particles of up to approximately 100-200 μm in diameter are perceived to be only moderately troublesome on swallowing. [0011]
    [0012] Film-forming polymers which can be employed for the production of a saliva-resistant coating are known to the person skilled in the art. Frequently, a copolymer based on dimethylaminoethyl methacrylate and neutral methacrylic acid esters having the trade name Eudragit E (Röhm) is employed for this purpose. The basic character of the dimethylaminoethyl methacrylate provides for solubility in the acidic medium, such as, for example, in the gastric juice, while the solubility in the relatively neutral saliva is rather low. If the thickness of the film is suitable, a coating can therefore be produced using this copolymer which resists disintegration in the saliva for a longer time, but which dissolves rapidly in the stomach. Alternatively, all other film-forming polymers which have a markedly better solubility in the gastric juice than in the saliva can be used for this purpose. [0012]
    [0013] Release-delaying film coatings are widespread in the technology of solid oral presentation forms. The polymers employed for this typically have a low solubility in aqueous media both at acidic and at neutral to basic pHs. With sufficient thickness and mechanical strength of the film coating, this dissolves neither in the saliva nor in the gastric or intestinal juice. On the other hand, the thickness must not be too great, since the film coating must allow the diffusion of water into the active compound reservoir, where the active compound is continuously dissolved and diffuses outwards through the coating in dissolved form. A large number of polymers have been employed for this purpose; examples which may be mentioned are: polymers from the group consisting of the cellulose esters, such as, for example, cellulose acetate, representatives of the cellulose ethers group, such as, for example, ethylcellulose, certain poly(meth)acrylic acid derivatives, e.g. Eudragit RL or RS (Röhm) and certain polyvinyl derivatives such as polyvinyl acetate. [0013]
    [0014] The polymers typically used for the preparation of film coatings which are resistant to gastric juice but soluble in small intestinal juice have an extremely low solubility in the acidic medium with markedly better solubility in the neutral pH range. These properties are seen especially in those polymers which contain acidic groups which are present in undissociated form in the gastric juice. Examples which may be mentioned are: hemiesters of divalent acids such as succinic or phthalic acid with cellulose ethers, cellulose esters, polyvinyl derivatives, carboxymethylcelluloses or poly(meth)acrylic acids, such as are contained in Eudragit L or S (Röhm). [0014]
    [0015] Elasticity and strength of the film coatings of the particles are a prerequisite for the functionality of the pharmaceutical form, since the coatings must not be damaged by the strong mechanical stress during compression or tabletting; at least the predominant majority of the particles contained in the lozenge should have two intact coating layers within the meaning of the invention. It is known to the person skilled in the art that the elasticity, flexibility and strength of the polymer films is dependent on the polymer type, molecular weight, degree of substitution of the film-forming agents employed, but also on the nature and amount of the additives employed. In particular, plasticizers or additives employed for other purposes, but which have a plasticizing action, have a considerable effect on the mechanical film properties. For most of the polymers which can be employed within the meaning of the invention, the prior art knows suitable plasticizers for the production of certain mechanical properties; the person skilled in the art is able by means of suitable experiments to determine the optimum amount of plasticizer for the purpose of the tabletting according to the invention of coated particles, which can differ completely from the amount recommended for other purposes. [0015]
    [0016] Two examples should serve to illustrate possible embodiments of the invention which, however, only have illustrative character; the person skilled in the art is able to develop further examples using different recipes and preparation processes. [0016] EXAMPLE 1
    [0017] Lozenges of enteric-coated ibuprofen particles comprising 600 mg of ibuprofen [0017]
    [0018] Ibuprofen micropellets are first prepared by granulating, extruding and spheronizing. For this, 700 g of ibuprofen, 180 g of microcrystalline cellulose and 120 g of lactose monohydrate are mixed in a powder blender and then made into a paste in a suitable kneader mixer with addition of n g of water to give a mass having a kneadable consistency. The mass is extruded through a specially made perforated disc having a hole diameter of 300 μm using an extruder, e.g. a single-screw extruder of the E 40/10 D type (Gabler), cut and, if possible, rounded in the on-line process, e.g. in a spheronizer of the type (Gabler) R 250. The micropellets are then dried in a dryer to a residual moisture of about 2-3%, which can be carried out in a suitable fluidized bed apparatus, but preferably in the apparatus intended for the coating of the pellets, e.g. the fluidized bed granulator/dryer/coater of the Uni-Glatt type (Glatt). For the production of the first, enteric-coating, the pellets are sprayed into the fluidized bed via a two-substance nozzle at about 1-2 bar in the top-spray arrangement and at a spray velocity of 10 ml/min with a dispersion of 95 g of Eudragit® L30 D-55, 45 g of Eudragit® NE 30 D (both Röhm), 8 g of triethyl citrate, 12 g of polyethylene glycol 6000, 20 g of talc and 90 g of water up to a dry weight increase of 12%. A suitable spray temperature is 38-43°C., and subsequent drying at 30-35° C. should take place. [0018]
    [0019] The enteric-coated particles prepared in this way are then provided according to the invention with a second, saliva-resistant coating. Alternatively, the production of the saliva resistance can also be carried out without transition by means of a change in the spray medium in the preceding process. A suitable spray solution for this is composed of 240 g of Eudragit® E 12.5, 18 g of polyethylene glycol 6000, 12 g of microcrystalline cellulose, 12 g of magnesium stearate and 220 g of acetone. It can be sprayed into the apparatus described above at the same pressure and the same spray velocity, but preferably at a temperature reduced to about 30° C. The spray process is complete with a weight increase in the pellets of 11%. [0019]
    [0020] After the subsequent drying, the particles now provided with two coatings are compressed to give lozenges. For this, 1066 g of pellets—these contain 600 g of ibuprofen —are mixed in a powder blender with 260 g of sorbitol (a directly tablettable quality is necessary), 2 g of colloidal silica, 28 g of stearic acid and 11 g of magnesium stearate and pressed in a tablet press to give tablets weighing 1367 mg, e.g. with a diameter of 18 mm. [0020] EXAMPLE 2
    [0021] Lozenges of release-delaying coated ibuprofen particles comprising 600 mg of ibuprofen [0021]
    [0022] The preparation is carried out analogously to Example 1 with the assumption that a dispersion of 110 g of Eudragit RS 30 D, 25 g of talc, 28 g of triethyl citrate and 15 g of polyethylene glycol 6000 is used for the production of the release-modifying coating. [0022]
    [0023] These working examples illustrate the principle of the invention; depending on prioritization of the product properties, e.g. low particle sizes for the sensory improvement of the sucking or disintegration properties of the tablet or lower auxiliary contents for the reduction of the production costs, they can be markedly optimized in the direction of one of the target parameters. [0023]
    权利要求:
    Claims (19)
    [1" id="US-20010001668-A1-CLM-00001] 1. Pharmaceutical lozenge pressed from pulverulent or granular press material, characterized in that the press material contains an active-compound preparation in the form of at least two-layer coated particles in addition to customary auxiliaries suitable for the production of lozenges, an outer coating layer being saliva-resistant, but soluble in gastric juice, and an inner coating layer being largely disintegration-resistant in aqueous media, but allowing a delayed release of active compound by diffusion.
    [2" id="US-20010001668-A1-CLM-00002] 2. Pharmaceutical lozenge pressed from pulverulent or granular press material, characterized in that the press material contains an active-compound preparation in the form of at least two-layer coated particles in addition to customary auxiliaries suitable for the production of lozenges, an outer coating layer being saliva-resistant, but soluble in gastric juice, and an inner coating layer being gastric juice-resistant, but soluble in the small intestine.
    [3" id="US-20010001668-A1-CLM-00003] 3. Pharmaceutical lozenge according to
    claim 1 or
    2 , characterized in that the saliva-resistant, but gastric juice-soluble coating layer contains as film-forming agent one or more polymers from the group consisting of the dimethylaminoethyl methacrylates and the methacrylic acid esters.
    [4" id="US-20010001668-A1-CLM-00004] 4. Pharmaceutical lozenge according to
    claim 1 , characterized in that the coating layer delaying the release of active compound contains as film-forming agent one or more polymers from the group consisting of the cellulose ethers, cellulose esters, polyacrylic acid derivatives, polymethacrylic acid derivatives and polyvinyl derivatives.
    [5" id="US-20010001668-A1-CLM-00005] 5. Pharmaceutical lozenge according to
    claim 2 , characterized in that the gastric juice-resistant coating layer contains as film-forming agent one or more polymers from the group consisting of the cellulose ether, cellulose ester or polyvinyl acetate phthalates or succinates, the carboxymethylcelluloses, the polyacrylic acid derivatives and the polymethacrylic acid derivatives.
    [6" id="US-20010001668-A1-CLM-00006] 6. Pharmaceutical lozenge according to one of the preceding claims, characterized in that the film coatings, in addition to film-forming polymers, contain those pharmaceutically acceptable auxiliaries which are able to increase the flexibility of the film coatings.
    [7" id="US-20010001668-A1-CLM-00007] 7. Process for the production of pharmaceutical lozenges according to one of the preceding claims, characterized in that in a first process step, by means of an agglomeration process, a multiparticulate preparation is prepared from a mixture of active compound and suitable auxiliaries, whose particles are coated in a second process step in a spray application process first with an active-compound-delaying or enteric film coating, then with a saliva-resistant, but gastric juice-soluble film coating, and compressed together with further auxiliaries in a tablet machine in a third process step to give lozenges.
    [8" id="US-20010001668-A1-CLM-00008] 8. Pharmaceutical lozenge pressed from pulverulent or granular press material wherein the press material contains an active-compound preparation in the form of at least two-layer coated particles in addition to customary auxiliaries suitable for the production of lozenges, an outer coating layer being saliva-resistant, but soluble in gastric juice, and an inner coating layer being largely disintegration resistant in aqueous media, but allowing a delayed release of active compound by diffusion.
    [9" id="US-20010001668-A1-CLM-00009] 9. Pharmaceutical lozenge pressed from pulverulent or granular press material wherein the press material contains an active-compound preparation in the form of at least two-layer coated particles in addition to customary auxiliaries suitable for the production of lozenges, an outer layer being saliva-resistant, but soluble in gastric juice, and an inner coating layer being gastric juice-resistant, but soluble in the small intestine.
    [10" id="US-20010001668-A1-CLM-00010] 10. The pharmaceutical lozenge of
    claim 8 wherein the saliva-resistant, but gastric juice-soluble coating layer contains a film-forming agent comprising one or more polymers selected from the group consisting of the dimethylaminoethyl methacrylates and the methacrylic acid esters.
    [11" id="US-20010001668-A1-CLM-00011] 11. The pharmaceutical lozenge of
    claim 9 wherein the saliva-resistant, but gastric juice-soluble layer coating layer contains a film-forming agent comprising one or more polymers selected from the group consisting of the dimethylaminoethyl methacrylates and the methacrylic acid esters.
    [12" id="US-20010001668-A1-CLM-00012] 12. The pharmaceutical lozenge of
    claim 8 wherein the coating layer delaying the release of active compound contains a film-forming agent comprising one or more polymers selected from the group consisting of the cellulose ethers, cellulose esters, polyacrylic acid derivatives, polymethacrylic acid derivatives and polyvinyl derivatives.
    [13" id="US-20010001668-A1-CLM-00013] 13. The pharmaceutical lozenge of
    claim 9 wherein the gastric juice-resistant coating layer contains a film-forming agent comprising one or more polymers selected from the group consisting of the cellulose ether, cellulose ester or polyvinyl acetate phthalates or succinates, the carboxymethylcelluloses, the polyacrylic acid derivatives and the polymethacrylic acid derivatives.
    [14" id="US-20010001668-A1-CLM-00014] 14. The pharmaceutical composition of
    claim 10 comprising film coatings which in addition to the film-forming polymers further comprise pharmaceutically acceptable auxiliaries which increase the flexibility of the film coatings.
    [15" id="US-20010001668-A1-CLM-00015] 15. The pharmaceutical composition of
    claim 11 comprising film coatings which in addition to the film-forming polymers further comprise pharmaceutically acceptable auxiliaries which increase the flexibility of the film coatings.
    [16" id="US-20010001668-A1-CLM-00016] 16. The pharmaceutical composition of
    claim 12 comprising film coatings which in addition to the film-forming polymers further comprise pharmaceutically acceptable auxiliaries which increase the flexibility of the film coatings.
    [17" id="US-20010001668-A1-CLM-00017] 17. The pharmaceutical composition of
    claim 13 comprising film coatings which in addition to the film-forming polymers further comprise pharmaceutically acceptable auxiliaries which increase the flexibility of the film coatings.
    [18" id="US-20010001668-A1-CLM-00018] 18. Process of the production of a pharmaceutical lozenge of
    claim 8 comprising:
    (a) producing a multiparticulate preparation from a mixture of active compound and suitable auxiliaries by an agglomeration process;
    (b) coating the particles of said multiparticulate preparation produced in step (a) in a spray application first with an active-compound-delaying or enteric film coating and then with a saliva-resistant, but gastric juice-soluble film coating; and
    (c) compressing the coated particles produced in step (b) with further auxiliaries in a tablet machine to produce a lozenge.
    [19" id="US-20010001668-A1-CLM-00019] 19. Process of the production of a pharmaceutical lozenge of
    claim 9 comprising:
    (a) producing a multiparticulate preparation from a mixture of active compound and suitable auxiliaries by an agglomeration process;
    (b) coating the particles of said multiparticulate preparation produced in step (a) in a spray application first with an active-compound-delaying or enteric film coating and then with a saliva-resistant, but gastric juice-soluble film coating; and
    (c) compressing the coated particles produced in step (b) with further auxiliaries in a tablet machine to produce a lozenge.
    类似技术:
    公开号 | 公开日 | 专利标题
    US6270798B2|2001-08-07|Lozenge for the modified releasing of active substances in the gastrointestinal tract
    EP1166777B1|2008-08-13|Taste masked pharmaceutical particles
    US5552152A|1996-09-03|Taste masking of ibuprofen by fluid bed coating
    US4713248A|1987-12-15|Diffusion coated multiple-units dosage form
    EP1276469B1|2007-06-13|Taste masking coating composition
    US6174548B1|2001-01-16|Omeprazole formulation
    AU783593B2|2005-11-10|Texture masked particles containing an active ingredient
    KR101157220B1|2012-07-09|Gastroresistant pharmaceutical formulations containing rifaximin
    US5489436A|1996-02-06|Taste mask coatings for preparation of chewable pharmaceutical tablets
    US20060204587A1|2006-09-14|Use of film coating as taste-masking coating of oral dosage forms
    US20120128764A1|2012-05-24|Controlled-release compositions comprising a proton pump inhibitor
    HU0402230A2|2005-02-28|Pharmaceutical dosage form with multiple coatings
    CA2630235A1|2007-07-12|Lansoprazole orally disintegrating tablets
    JP2004507487A|2004-03-11|Intestinal disease drug
    AU2005204017B2|2008-01-31|Controlled release pharmaceutical composition comprising an acid-insoluble polymer and a bioadhesive polymer
    RU2744270C2|2021-03-04|Compressed pharmaceutical product
    MXPA99004759A|2000-02-02|Lozenge for the modified releasing of active substances in the gastrointestinal tract
    MXPA06007780A|2006-12-13|Controlled release pharmaceutical composition comprising an acid-insoluble and a bioadhesive polymer
    同族专利:
    公开号 | 公开日
    EP0941070A2|1999-09-15|
    ES2196381T3|2003-12-16|
    AU5322598A|1998-06-22|
    AU725493B2|2000-10-12|
    EP0941070B1|2003-03-26|
    DE59709645D1|2003-04-30|
    US6270798B2|2001-08-07|
    CA2272442C|2004-05-11|
    KR20000057205A|2000-09-15|
    CA2272442A1|1998-06-04|
    JP2001527526A|2001-12-25|
    KR100429489B1|2004-05-03|
    DE19648576A1|1998-06-04|
    WO1998023262A3|1998-09-11|
    DE19648576C2|1999-08-12|
    AT235232T|2003-04-15|
    NO992477D0|1999-05-21|
    NO992477L|1999-05-21|
    WO1998023262A2|1998-06-04|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    EP2557938A1|2010-01-15|2013-02-20|Kemin Industries, Inc.|Protected alpha-amylase|
    US20150174079A1|2013-12-24|2015-06-25|Food for Health International, LLC|Lozenges with silver nanoparticles|FR2565107B1|1984-05-30|1986-09-05|Ucb Laboratoires|NOVEL MEDICINAL PRODUCT BASED ON ACTIVE CARBON AND ITS PREPARATION METHOD|
    EP0212745B1|1985-08-16|1991-04-10|The Procter & Gamble Company|Drug particles having constant release|
    US4786508A|1986-05-30|1988-11-22|Warner-Lambert Company|Coated dosage forms|
    US4800087A|1986-11-24|1989-01-24|Mehta Atul M|Taste-masked pharmaceutical compositions|
    JPS63258809A|1987-04-16|1988-10-26|Towa Yakuhin Kk|Fine granule having excellent releasing property of medicinally active ingredient and masked bitterness|
    JP2573969B2|1987-10-21|1997-01-22|帝國製薬株式会社|Drug Intermittent Release Oral Formulation|
    WO1991015194A1|1990-04-11|1991-10-17|The Upjohn Company|Taste masking of ibuprofen by fluid bed coating|
    IT1246383B|1990-04-17|1994-11-18|Eurand Int|METHOD FOR MASKING THE TASTE OF DRUGS|
    US5460825A|1990-05-23|1995-10-24|Mcneil-Ppc, Inc.|Taste mask coatings for preparing chewable pharmaceutical tablets|
    AU8219191A|1990-06-14|1992-01-07|Kalmo Enterprises, Inc.|Stable aqueous drug suspensions|
    US5464632C1|1991-07-22|2001-02-20|Prographarm Lab|Rapidly disintegratable multiparticular tablet|
    AT217789T|1992-06-04|2002-06-15|Smithkline Beecham Corp|PLEASANT TASTING PHARMACEUTICAL COMPOSITIONS|
    IT1256651B|1992-12-11|1995-12-12|Giancarlo Santus|PHARMACEUTICAL COMPOSITION WITH CONTROLLED RELEASE IN LIQUID SUSPENSION|
    DE4333190C2|1993-09-29|1996-05-30|Korsatko Werner Univ Prof Dr E|Bite-coated tablet with delayed release of active ingredient|DE19849848A1|1998-10-29|2000-05-04|Lohmann Therapie Syst Lts|Oral application, spontaneous disintegration with liquid and dosage form and process for its preparation|
    DE19933148A1|1999-07-20|2001-01-25|Boehringer Ingelheim Int|Lozenge containing ambroxol|
    US20060251722A1|2005-05-03|2006-11-09|Novavax, Inc.|Multi-component vitamin and mineral supplement for the optimal absorption of components|
    AR077712A1|2009-08-05|2011-09-14|Idenix Pharmaceuticals Inc|SERINA PROTEASA MACROCICLICA INHIBITORS|
    WO2011056764A1|2009-11-05|2011-05-12|Ambit Biosciences Corp.|Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles|
    MY159958A|2009-12-18|2017-02-15|Idenix Pharmaceuticals Inc|5,5-fused arylene or heteroarylene hepatitis c virus inhibitors|
    WO2011094890A1|2010-02-02|2011-08-11|Argusina Inc.|Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators|
    WO2011112689A2|2010-03-11|2011-09-15|Ambit Biosciences Corp.|Saltz of an indazolylpyrrolotriazine|
    MX2013002383A|2010-09-01|2013-07-05|Ambit Biosciences Corp|Hydrobromide salts of a pyrazolylaminoquinazoline.|
    AU2011296074B2|2010-09-01|2015-06-18|Ambit Biosciences Corporation|An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof|
    EP3178465A1|2010-12-06|2017-06-14|Follica, Inc.|Methods for treating baldness and promoting hair growth|
    WO2012080050A1|2010-12-14|2012-06-21|F. Hoffmann-La Roche Ag|Solid forms of a phenoxybenzenesulfonyl compound|
    US9393255B2|2011-01-31|2016-07-19|Celgene Corporation|Pharmaceutical compositions of cytidine analogs and methods of use thereof|
    WO2012109398A1|2011-02-10|2012-08-16|Idenix Pharmaceuticals, Inc.|Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections|
    US20120252721A1|2011-03-31|2012-10-04|Idenix Pharmaceuticals, Inc.|Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor|
    MX2014011115A|2012-03-16|2015-03-13|Axikin Pharmaceuticals Inc|3,5-diaminopyrazole kinase inhibitors.|
    DK2833880T3|2012-04-02|2017-12-04|Pharma Seeds Create Llc|Oral solid dosage composition with ibuprofen comprising a methacrylic acid copolymer|
    NZ631142A|2013-09-18|2016-03-31|Axikin Pharmaceuticals Inc|Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors|
    US20160229866A1|2013-09-20|2016-08-11|Idenix Pharmaceuticals Inc.|Hepatitis c virus inhibitors|
    EP3114122A1|2014-03-05|2017-01-11|Idenix Pharmaceuticals LLC|Solid forms of a flaviviridae virus inhibitor compound and salts thereof|
    RU2741914C2|2014-03-20|2021-01-29|Капелла Терапьютикс, Инк.|Benzimidazole derivatives as erbb tyrosine kinase inhibitors for treating cancer|
    WO2015143161A1|2014-03-20|2015-09-24|Capella Therapeutics, Inc.|Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer|
    HUE049801T2|2014-12-23|2020-10-28|Sma Therapeutics Inc|3,5-diaminopyrazole kinase inhibitors|
    法律状态:
    1999-07-06| AS| Assignment|Owner name: LTS LOHMANN THERAPIE-SYSTEME GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CREMER, KARSTEN;REEL/FRAME:010098/0804 Effective date: 19990529 |
    2001-01-31| AS| Assignment|Owner name: LTS LOHMANN THERAPIE-SYSTEME AG, GERMANY Free format text: CHANGE OF NAME;ASSIGNOR:LTS LOHMANN THERAPIE-SYSTEME GMBH;REEL/FRAME:011521/0700 Effective date: 19990917 |
    2005-02-01| FPAY| Fee payment|Year of fee payment: 4 |
    2009-02-16| REMI| Maintenance fee reminder mailed|
    2009-08-07| LAPS| Lapse for failure to pay maintenance fees|
    2009-09-07| STCH| Information on status: patent discontinuation|Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
    2009-09-29| FP| Lapsed due to failure to pay maintenance fee|Effective date: 20090807 |
    优先权:
    申请号 | 申请日 | 专利标题
    DE19648576||1996-11-23||
    DE19648576A|DE19648576C2|1996-11-23|1996-11-23|Lozenge for modified release of active substances in the gastrointestinal tract|
    EP19648576.2||1996-11-23||
    PCT/EP1997/006395|WO1998023262A2|1996-11-23|1997-11-17|Lozenge for the modified releasing of active substances in the gastrointestinal tract|
    [返回顶部]